PARP Inhibitors and Proteins Interacting with SLX4 - CRCL-OncoPharmacologie Access content directly
Journal Articles (Review Article) Cancers Year : 2023

PARP Inhibitors and Proteins Interacting with SLX4


PARP inhibitors are small molecules currently used with success in the treatment of certain cancer patients. Their action was first shown to be specific to cells with DNA repair deficiencies, such as BRCA-mutant cancers. However, recent work has suggested clinical interest of these drugs beyond this group of patients. Preclinical data on relationships between the activity of PARP inhibitors and other proteins involved in DNA repair exist, and this review will only highlight findings on the SLX4 protein and its interacting protein partners. As suggested from these available data and depending on further validations, new treatment strategies could be developed in order to broaden the use for PARP inhibitors in cancer patients.
Fichier principal
Vignette du fichier
Jordheim LP 2023 Cancers.pdf (439.8 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04164299 , version 1 (18-07-2023)



Lars Petter Jordheim. PARP Inhibitors and Proteins Interacting with SLX4. Cancers, 2023, 15, ⟨10.3390/cancers15030997⟩. ⟨hal-04164299⟩
31 View
12 Download



Gmail Mastodon Facebook X LinkedIn More